Articles

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)

Department of Internal Medicine III, Ulm University, Ulm, Germany
University of Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France
Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany
Department of Clinical Hematology, University Hospital of Montpellier, Montpellier, France
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany
Duchossois Center for Advanced Medicine, University of Chicago Medicine, Chicago, IL, USA
Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
Department of Pathology, The Ohio State University, Columbus, OH, USA
Genentech Inc, South San Francisco, CA, USA
F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada
Roche Products Ltd, Welwyn Garden City, UK
AbbVie Inc, North Chicago, IL, USA
Roche Products Ltd, Welwyn Garden City, UK
Genentech Inc, South San Francisco, CA, USA
Hospices Civils de Lyon, Université de Lyon, Pierre-Bénite, France
Haematologica Early view Oct 29, 2020 https://doi.org/10.3324/haematol.2020.261107